Home » AMEX » AMEX TRADED STOCKS » ACAD () AMEX Stocks : ACAD () on Investors NewsDesk Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ... Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss? Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting 3 Pharma Stocks to Sell in April Before They Crash & Burn ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development Yahoo! Finance: ACAD News